CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP MOUTHWASH

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

CHLORHEXIDINE GLUCONATE

Disponible des:

SAGE PRODUCTS LLC

Codi ATC:

A01AB03

Designació comuna internacional (DCI):

CHLORHEXIDINE

Dosis:

0.12%

formulario farmacéutico:

MOUTHWASH

Composición:

CHLORHEXIDINE GLUCONATE 0.12%

Vía de administración:

BUCCAL

Unidades en paquete:

15ML/473ML

tipo de receta:

Prescription

Área terapéutica:

MISCELLANEOUS ANTI-INFECTIVES

Resumen del producto:

Active ingredient group (AIG) number: 0107629007; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2022-04-22

Fitxa tècnica

_ _
_ _
_Page 1 of 19_
PRODUCT MONOGRAPH
CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP
Chlorhexidine Gluconate 0.12% Oral Rinse
Liquid, 0.12% Chlorhexidine Gluconate
Antigingivital Oral Rinse
Sage Product LLC
3909 Three Oaks Road
Cary, IL 60013
USA
Date of Preparation:
February 17, 2015
Submission Control No: 180308
_ _
_ _
_Page 2 of 19_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................6
OVERDOSAGE
..................................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEUTICAL INFORMATION
..........................................................................11
CLINICAL TRIALS
..........................................................................................................12
DETAILED PHARMACOLOGY
.........................